170 related articles for article (PubMed ID: 33504137)
1. Cutaneous Anaplastic Large-Cell Lymphoma with Dramatic Response to Brentuximab Vedotin.
Şahin M; Miskioğlu M; İnanır I; Akar H; Neşe N; Temiz P; Aydoğdu İ
Turk J Haematol; 2021 Feb; 38(1):85-87. PubMed ID: 33504137
[No Abstract] [Full Text] [Related]
2. Brentuximab vedotin in multifocal cutaneous anaplastic large cell lymphoma in a patient with human immunodeficiency virus following Hodgkin lymphoma.
Wolf S; Goiriz R; Dhairyawan R; Paige D; Rizvi H; Haroon A; Montoto S
Clin Exp Dermatol; 2019 Jul; 44(5):562-564. PubMed ID: 30430604
[No Abstract] [Full Text] [Related]
3. Primary cutaneous anaplastic large-cell lymphoma successfully treated with intralesional brentuximab vedotin: a case report.
Arroyo-Andrés J; Agud-Dios M; Rubio-Muniz CA; Vico-Alonso C; Cortijo-Cascajares S; Ortiz-Romero PL
Int J Dermatol; 2022 Jul; 61(7):e267-e269. PubMed ID: 34363613
[No Abstract] [Full Text] [Related]
4. Successful Employment of Brentuximab Vedotin in a Patient Undergoing Hemodialysis: The First Real-life Experience.
Nanni L; Pellegrini C; Stefoni V; Argnani L; Cavo M; Zinzani PL
Clin Lymphoma Myeloma Leuk; 2019 Nov; 19(11):e595-e596. PubMed ID: 31543370
[No Abstract] [Full Text] [Related]
5. [Brentuximab vedotin for previously untreated systemic anaplastic large cell lymphoma].
Calleja A; Bouclet F
Bull Cancer; 2021 Jan; 108(1):12-13. PubMed ID: 33308986
[No Abstract] [Full Text] [Related]
6. RF - Brentuximab as Treatment for CD30
Morgado-Carrasco D; Combalia A; Estrach Panella T
Actas Dermosifiliogr (Engl Ed); 2019 Nov; 110(9):769-770. PubMed ID: 31151669
[No Abstract] [Full Text] [Related]
7. Isolated Central Nervous System Progression During Systemic Treatment With Brentuximab Vedotin Monotherapy in a Pediatric Patient With Recurrent ALK-negative Anaplastic Large Cell Lymphoma.
Kim Y; Sudo A; Oyama R; Keino D; Tomizawa D; Kato M; Osumi T; Mori T
J Pediatr Hematol Oncol; 2021 Aug; 43(6):e864-e866. PubMed ID: 32769561
[TBL] [Abstract][Full Text] [Related]
8.
Wang M; Kibbi N; Ring N; Siddon A; Foss F; Totonchy M
BMJ Case Rep; 2019 Sep; 12(9):. PubMed ID: 31570354
[TBL] [Abstract][Full Text] [Related]
9. Improvement of Cutaneous Anaplastic Large Cell Lymphoma by Brentuximab Vedotin Monotherapy.
Onaka T; Kitagawa T; Kawakami C; Yonezawa A
Turk J Haematol; 2018 May; 35(2):135-136. PubMed ID: 29391331
[No Abstract] [Full Text] [Related]
10. Early and sustained remission with brentuximab vedotin in a case of disseminated cutaneous relapse from systemic anaplastic large cell lymphoma refractory to chemotherapy.
Aguiar-Bujanda D; Dueñas-Comino A; Cabello C; Bastida J; Rivero-Vera JC; Limeres-González MA
Eur J Dermatol; 2017 Dec; 27(6):671-673. PubMed ID: 29165301
[No Abstract] [Full Text] [Related]
11. Efficacy and safety of Brentuximab Vedotin in advanced cutaneous T-Cell lymphomas patients.
Papadavid E; Kapniari E; Marinos L; Nikolaou V; Oikonomidi A; Georgakopoulos J; Stratigos A; Kouloulias V; Pappa V
J Eur Acad Dermatol Venereol; 2019 May; 33(5):e223-e225. PubMed ID: 30821007
[No Abstract] [Full Text] [Related]
12. Population-based cohort study of the efficacy of brentuximab vedotin in relapsed systemic anaplastic large-cell lymphoma using Public Health England data.
Halligan SJ; Grainge MJ; Martinez-Calle N; Fox CP; Bishton MJ
Br J Haematol; 2022 Feb; 196(4):932-938. PubMed ID: 34664265
[TBL] [Abstract][Full Text] [Related]
13. Remission of refractory granulomatous primary cutaneous anaplastic large cell lymphoma to brentuximab vedotin.
Sasapu A; Dunn ALJ; Gardner J; Wong HK
BMJ Case Rep; 2021 Jul; 14(7):. PubMed ID: 34290015
[TBL] [Abstract][Full Text] [Related]
14. Safety profile of brentuximab vedotin in Japanese patients with relapsed/refractory Hodgkin lymphoma or systemic anaplastic large cell lymphoma: a post-marketing surveillance study.
Izutsu K; Ogura M; Tobinai K; Hatake K; Sakamoto S; Nishimura M; Hoshino M
Int J Hematol; 2021 Mar; 113(3):404-412. PubMed ID: 33392974
[TBL] [Abstract][Full Text] [Related]
15. Brentuximab Vedotin in the Treatment of Peripheral T Cell Lymphoma and Cutaneous T Cell Lymphoma.
Shea L; Mehta-Shah N
Curr Hematol Malig Rep; 2020 Feb; 15(1):9-19. PubMed ID: 32016790
[TBL] [Abstract][Full Text] [Related]
16. Transformation of Grade I Follicular Lymphoma to Anaplastic Large Cell Lymphoma CD30+ ALK1- with Complete Response to Brentuximab Vedotin and High-Dose Methotrexate.
Al-Mansour M; Al-Maghraby H; Shirah B
Gulf J Oncolog; 2020 May; 1(33):87-90. PubMed ID: 32476657
[TBL] [Abstract][Full Text] [Related]
17. A pilot study of weekly brentuximab vedotin in patients with CD30+ malignancies resistant to brentuximab vedotin every 3 weeks.
Poston JN; Fromm JR; Rasmussen HA; Shustov AR; Libby EN; Smith SD; Gooley T; Gopal AK
Br J Haematol; 2019 Jul; 186(1):159-162. PubMed ID: 30592026
[No Abstract] [Full Text] [Related]
18. Brentuximab vedotin in T-cell lymphoma.
Van Der Weyden C; Dickinson M; Whisstock J; Prince HM
Expert Rev Hematol; 2019 Jan; 12(1):5-19. PubMed ID: 30526166
[TBL] [Abstract][Full Text] [Related]
19. Variable loss of CD30 expression by immunohistochemistry in recurrent cutaneous CD30+ lymphoid neoplasms treated with brentuximab vedotin.
Goyal A; Patel S; Goyal K; Morgan EA; Foreman RK
J Cutan Pathol; 2019 Nov; 46(11):823-829. PubMed ID: 31286556
[TBL] [Abstract][Full Text] [Related]
20. Patient-reported quality of life in patients with relapsed/refractory cutaneous T-cell lymphoma: Results from the randomised phase III ALCANZA study.
Dummer R; Prince HM; Whittaker S; Horwitz SM; Kim YH; Scarisbrick J; Quaglino P; Zinzani PL; Wolter P; Eradat H; Pinter-Brown L; Sanches JA; Ortiz-Romero PL; Akilov OE; Geskin L; Huen A; Walewski J; Wang Y; Lisano J; Richhariya A; Feliciano J; Zhu Y; Bunn V; Little M; Zagadailov E; Dalal MR; Duvic M
Eur J Cancer; 2020 Jul; 133():120-130. PubMed ID: 32502876
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
